CS
Champions Oncology, Inc.
CSBR · NASDAQ
$4.84 -2.81% (-$0.14)
1M -5.10%
Market Cap $69.2M
P/E Ratio -
Div. Yield -
ROE 27.88%
Bulios Fair Price
$7.19
48.6% upside
Current Price
$4.84
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CSBR is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
20 /100
Expensive P/S 1.52x
P/B 17.77x
EV/EBITDA 561.79x
Growth
0 /100
Declining Book val. growth 5.29%
Rev. growth N/A
FCF growth N/A
Profitability
12 /100
Weak Net margin 2.50%
Op. margin 2.29%
FCF margin 13.51%
Quality
15 /100
Poor ROE 27.88%
ROA 3.41%
Asset turnover 1.36x
Debt
8 /100
High Current ratio 1.03x
Net debt/EBITDA 41.56x
Debt/Equity 2.54x
Stability
15 /100
Unstable Rev. volatility 60.52%
EPS volatility 146.41%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CSBR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Brainin
Employees
214
Headquarters
Hackensack
Upcoming events
15 DEC
Earnings
Upcoming earnings report